Skip to main content
MPLT
NASDAQ Life Sciences

MapLight 10-Q Confirms $51.6M Q3 Loss, $463.4M Cash Through 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$7.37
Mkt Cap
$402.924M
52W Low
$6.06
52W High
$40.43
52W Position info
22% above low
Off High info
82% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

MPLT sits 22% above its 52-week low of $6.06.

Summary

MapLight's 10-Q confirms the $51.6 million Q3 loss and $463.4 million cash pile disclosed in today's 8-K, with runway through 2028 and full detail on the $140.1 million August private placement.


Key Events · Earnings and Guidance · MPLT

  • Q3 Loss Widens to $51.6M

    Net loss was $51.6 million ($0.97 per share) versus $29.4 million ($37.18 per share) in Q3 2025, driven by R&D of $44.2 million and G&A of $11.1 million.

  • Cash Runway Through 2028

    Cash, cash equivalents and investments totaled $463.4 million at September 30, 2026; nine-month operating cash burn was $131.7 million.

  • August Placement Terms Detailed

    9,197,887 shares at $11.38 plus 3,983,168 pre-funded warrants at $11.3799 per underlying share, for $140.1 million net after $10.0 million of fees and expenses.

  • Vanderbilt License Amended

    September 2026 amendment adds a $0.4 million one-time payment and revises aggregate milestones to up to $52.0 million, with sublicense revenue sharing of 2% to 50%.


Analysis · MPLT · Life Sciences

The full quarterly report backs up this morning's 8-K: a $51.6 million third-quarter loss ($0.97 per share) against $463.4 million in cash and investments that management says funds operations through 2028. The loss is wider than a year ago as R&D climbed to $44.2 million and G&A to $11.1 million, but the balance sheet removes any near-term financing pressure. The filing also details the August private placement — 9,197,887 shares at $11.38 plus 3,983,168 pre-funded warrants, $140.1 million net — and a September amendment to the Vanderbilt license that trimmed potential milestones to $52.0 million. What matters for holders is that the cash runway now extends past the key ZEPHYR-2 readout, so the story shifts from survival to clinical execution.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MPLT was trading at $7.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $402.9M. The 52-week trading range was $6.06 to $40.43. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MPLT - Latest Insights

MPLT
Nov 16, 2026, 7:20 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.37
Real-time Price: $7.37 info
Change: $0 (0%) info
Market Cap: $402.924M info
MPLT
Nov 16, 2026, 7:15 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.25
Real-time Price: $7.37 info
Change: +$0.120 (+2%) info
Market Cap: $402.924M info
MPLT
Aug 18, 2026, 6:55 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $11.59
Real-time Price: $7.37 info
Change: -$4.22 (-36%) info
Market Cap: $402.924M info
MPLT
Aug 18, 2026, 6:51 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $11.59
Real-time Price: $7.37 info
Change: -$4.22 (-36%) info
Market Cap: $402.924M info
MPLT
Aug 13, 2026, 5:01 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $11.70
Real-time Price: $7.37 info
Change: -$4.33 (-37%) info
Market Cap: $402.924M info